The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
At day 28 post-vaccination, higher immunogenicity was observed following Moderna vaccination compared to Novavax vaccination when given as a fourth dose in healthy adults for Ancestral and Omicron subvariants, including JN.1. However, local and systemic reactogenicity was higher in the Moderna vaccine group compared with the Novavax vaccine group. These results may have important implications for ongoing booster strategies.
Authors
- Lien Anh Ha (ORCID: https://orcid.org/0000-0002-2401-8980)
- Paul V. Licciardi (ORCID: https://orcid.org/0000-0001-6086-6285)
- Kim Mulholland (ORCID: https://orcid.org/0000-0001-7947-680X)
- Siddhartha Mahanty (ORCID: https://orcid.org/0000-0003-1068-0524)
- Rachel A. Higgins
- Emma Watts (ORCID: https://orcid.org/0000-0002-6309-6842)
- Cattram Nguyen (ORCID: https://orcid.org/0000-0002-0599-8645)
- Nadia Mazarakis (ORCID: https://orcid.org/0000-0001-7681-2775)
- John Hart (ORCID: https://orcid.org/0000-0002-9637-7974)
- Kerryn A. Moore (ORCID: https://orcid.org/0000-0002-8333-8271)
- Darren Suryawijaya Ong (ORCID: https://orcid.org/0000-0001-6409-1376)
- Claire von Mollendorf (ORCID: https://orcid.org/0000-0003-0927-1731)
- Kanta Subbarao (ORCID: https://orcid.org/0000-0003-1713-3056)
- Frances Justice
- Eleanor Neal (ORCID: https://orcid.org/0000-0001-7998-0942)
- Kathryn Bright
- Zheng Quan Toh (ORCID: https://orcid.org/0000-0002-0282-5837)
- Leanne Quah
- Yan Yung Ng
- Skyy Luu
- Shashini Dassanayake
- Anna Rudel
Institutions
- Peter Doherty Institute (AU)
- Murdoch Children's Research Institute (AU)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1016/j.jinf.2025.106447
- Citations
- 7
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 9.77
Funders
- Children’s Hospital of Wisconsin Research Institute
- Murdoch Children's Research Institute
- Coalition for Epidemic Preparedness Innovations